Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura.
about
Clinical indications for thrombopoietin and thrombopoietin-receptor agonistsAdvances in Diagnosis and Treatments for Immune ThrombocytopeniaRole of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopeniaChronic thrombocytopenia of childhood: use of non-invasive methods in clinical evaluation.Chronic refractory ITP in children: beyond splenectomy.Usefulness of measurement of reticulated platelets for diagnosis of idiopathic thrombocytopenic purpura.Autoimmune thrombocytopenia.Response to splenectomy is durable after a certain point in time in adult patients with chronic immune thrombocytopenic purpura.Management of patients with refractory immune thrombocytopenic purpura.Haematopoietic stem and progenitor cell-targeted therapies for thrombocytopenia.New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review.New insights and therapeutics for immune-mediated thrombocytopenia.Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura.Thrombocytopenia and hemostatic disorders in chronic graft versus host disease.Treatment of immune thrombocytopenic purpura: focus on eltrombopag.Thrombopoietin and platelet production in chronic immune thrombocytopenia.New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.Toxicities of the thrombopoietic growth factorsPopulation pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura.Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations.Current treatment options for primary immune thrombocytopenia.Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia.The development of romiplostim for patients with immune thrombocytopenia.Thrombopoietin and hematopoietic stem cells.Eltrombopag for the treatment of immune thrombocytopenia.Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile.Recombinant human thrombopoietin alleviates infection-associated thrombocytopenia: a retrospective study in senile patients.The biology of thrombopoietin and thrombopoietin receptor agonists.Milestones in understanding platelet production: a historical overview.Immune Thrombocytopenic Purpura in Children and Adults: A Comparative Retrospective Study in IRANMulticenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia.Recombinant human thrombopoietin treatment promotes hematopoiesis recovery in patients with severe aplastic anemia receiving immunosuppressive therapy.A review of immune thrombocytopenic purpura: focus on the novel thrombopoietin agonistsThrombopoietin increases platelet adhesion under flow and decreases rolling.Pharmacokinetics of pegylated recombinant human megakaryocyte growth and development factor in healthy volunteers and patients with hematological disorders.Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety.
P2860
Q24601161-81245886-C697-4ED0-B35F-4FF707BDCB54Q26738630-2F56893E-141A-4F79-AA81-FEF0FA1428CBQ26741269-AF27EA8E-CF3A-4783-B346-D80760E05C5AQ33360453-B1C4A090-5668-4DED-A30C-6340081D3063Q33366005-999DCC43-36B1-4154-8341-7EE8391A550AQ33367271-DF87DD40-7864-4F6E-949B-34B351F0F2AAQ33367861-00CDFEFB-DCC7-4864-8C04-FBCB1AAFC3A6Q33370711-1D216FED-391A-44E6-9E8A-0583ABAD108CQ33372113-2767EF7D-3A4F-4C96-B3BA-31C86AF1262AQ33372720-F2C6056A-05B6-4E33-8761-F5AC98CA7142Q33377221-55C6EEF7-A1AE-4DD4-BC08-7D6B909E2FC8Q33377901-0911590C-7C81-48C5-A94D-024EC66346EDQ33385549-1BFB78DF-6C14-454E-84D8-F5FB47326DDBQ33385836-3AF02DA4-B066-464C-B329-49BA2EB54D95Q33385976-B604C308-D4B8-4102-BC2D-833B720089C3Q33387153-ECFF4F91-EFA6-4F30-8C1D-CF330EE72EB3Q33387735-D2D8B799-D0DF-4895-9749-93A5CBD2C56BQ33390645-85CF6F46-C1AA-45E8-BE3C-94E800E525A9Q33391013-40A8190C-536F-4109-9BBA-39576A8A7C6AQ33391229-CDA3CB9A-86DF-4D2F-A75B-76B71337F872Q33394149-D2ED47A9-6734-463D-8B4B-567E26191768Q33394438-E9F46BC8-0322-4DED-AA0A-C508DEEEB5D7Q33394636-308E9190-858E-475B-8407-49746E2A20A0Q33394846-F3082F46-3F21-415C-9E32-F423787696C9Q33395776-2DE8F1B9-02DB-49CD-B7F1-F1B3A21163FFQ33395943-0D32684E-8743-4F4A-84A4-AC31D6349F8DQ33400911-0A011EBA-3978-4299-B152-05A6CD11798AQ33406838-F1183E1E-1FA6-45AA-8346-90EC235BA0F9Q33407446-4D5249C7-9C19-4A51-9F7E-EC60DBB81740Q33408850-CC07D34F-2F03-49D8-847A-F9C5704B616FQ33413326-79AED536-2E0C-404B-A3E3-AB32D8A0CF22Q33420128-919CE608-9758-4B7E-9B95-02CC1F1224BCQ33427147-1F3AA3D0-17AC-4602-8D39-1AE58331543BQ35226647-FAA5340D-EDCC-4688-A4CC-C085269E931FQ35683792-AEB49684-C59B-43C3-AD74-21CC90249BEDQ44418477-B53E9087-4FA6-4773-BDB1-53E3C27E61ABQ54376489-49AB108E-B7CB-48B7-A89D-9A283F57FE5BQ54922450-EC351FF6-61B1-4B0B-A638-BDA8F1DF21F6
P2860
Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Effects of pegylated recombina ...... thic thrombocytopenic purpura.
@ast
Effects of pegylated recombina ...... thic thrombocytopenic purpura.
@en
type
label
Effects of pegylated recombina ...... thic thrombocytopenic purpura.
@ast
Effects of pegylated recombina ...... thic thrombocytopenic purpura.
@en
prefLabel
Effects of pegylated recombina ...... thic thrombocytopenic purpura.
@ast
Effects of pegylated recombina ...... thic thrombocytopenic purpura.
@en
P2093
P356
P1433
P1476
Effects of pegylated recombina ...... thic thrombocytopenic purpura.
@en
P2093
Kingo Fujimura
Shosaku Nomura
Tomomitsu Hotta
Yasuo Ikeda
P304
P356
10.1182/BLOOD.V100.2.728
P407
P577
2002-07-01T00:00:00Z